B24
Conditions
Interventions
Group 1: People living with HIV infection whose therapy was switched to a combination of doravirine/dolutegravir only (DoDo). Documentation of the treatment course from approx. 1 year before switching
Sponsors
Med. Klinik und Poliklinik IV, Sektion Klinische Infektiologie, LMU Klinikum Innenstadt, Ludwig-Maximilians-Universität München
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: • Persons being cared for in clinics and private practices in German-speaking areas • Age >18 years • documented HIV-1-infection • documented previous treatment with antiretroviral therapy (ART) • switch of ART to exclusively DOR/DTG • written informed consent after discussion of patient information
Exclusion criteria
Exclusion criteria: • Inability to consent • switch of ART to DOR/DTG in a clinic/practice not participating in the study • antiretroviral therapy including other substances except DOR/DTG
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1) Description of the clinical situation resulting in the prescriptrion of DOR/DTG as a 2-DR. 2) Documentation of the clinicaL and virological efficacy of the 2-DR DOR/DTG | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Frequency and causes for off-label prescription of the 2-DR DOR/DTG. 2) Durability of the 2-DR DOR/DTG: *Time to switch to another combination *Reason for switching to another combination | — |
Countries
Austria, Germany
Contacts
Public ContactUlrich Seybold
Med. Klinik und Poliklinik IV, Sektion Klinische Infektiologie, LMU Klinikum Innenstadt, Ludwig-Maximilians-Universität München
Outcome results
None listed